Went public 4/6/2000 at $15 apiece
Filing Range:5 mil. shares @ $15 to $17
Shares Outstanding:22.3 mil. shares
Chase H&Q/ING Barings/William Blair
(Data in $ millions)
Total Revenue $2.04 $2.18
Net Loss -3.29 -3.78
Sangamo BioSciences is involved in the research and development of novel transcription factors for the regulation of genes. Genes are composed of DNA and control the expression and transmission of all inherited traits. Transcription factors are proteins that turn genes on and turn genes off, or regulate gene expression, by recognizing specific DNA sequences. The company’s Universal Gene Recognition technology enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins, or ZFPs. ZFPs are the most abundant class of transcription factors in humans and other higher organisms and naturally function to regulate gene expression. By engineering ZFPs so that they can recognize a specific gene, the company has created ZFP transcription factors that can control gene expression and, consequently, cell function. Sangamo BioSciences intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, therapeutics for the treatment of human diseases, clinical diagnostics, and agricultural and industrial biotechnology. To that end, management has entered into collaborations with 18 pharmaceutical or biotechnolgoy companies.
Estimated net proceeds of $73.2 million will be used for research and development, capital expenditures and general corporate purposes.
JAFCO Co. Ltd., Lombard Odier & Cie, Stephens-Sangamo BioSciences LLC